The University of Minnesota is sixth — out of 153 universities — in the amount money made through the commercialization of university research, according to a study written up in MedCity News.
Ziagen (Abacavir) — used in the treatment of HIV — is a huge source of licensing income for the U. According to the Minnesota Daily in 2010:
… Royalties on the patent for Ziagen, an AIDS-combating drug manufactured by GlaxoSmithKline, accounted for over 90 percent of the (U of M Office for Technology Commercialization) revenues in fiscal year 2009.
In any case, the income has jumped recently, the Minnesota Daily wrote:
The University of Minnesota Office for Technology Commercialization’s revenues have nearly doubled in the past six years, from $48.4 million in 2004 to $95.2 million in 2009.
That said, regents have already discussed how that income could take a hit when the license runs out.
Below is the ranking. You can read the full story here.
1. Northwestern University, $161 million
2. Columbia University, $154 million
3. New York University, $113 million
4. University of California System, $103 million
5. Wake Forest University, $96 million
6. University of Minnesota, $95 million
7. University of Washington/Washington Research Foundation, $87 million
8. University of Massachusetts, $71 million
9. Massachusetts Institute of Technology, $66 million
10. Stanford University, $64 million
11. University of Wisconsin at Madison, $57 million
12. University of Florida, $54 million
13. California Institute of Technology, $48 million
14. University of Rochester, $46 million
15. University of Iowa Research Foundation, $43 million